Key result
Metabolic dysfunction-associated fatty liver disease linked to ~162% greater AF recurrence risk post-ablation.
Why the study?
In Asian patients with a higher prevalence of non-obese MAFLD, it was unclear whether MAFLD affects recurrence after AF ablation regardless of obesity.
Does the presence of MAFLD increase the risk of AF recurrence after ablation in Japanese patients?
Population
872 patients who underwent AF ablation
Comparison
Patients with MAFLD vs without MAFLD
Design
Retrospective study
Authors
Loading...
MAFLD may flag higher AF recurrence risk after ablation; hypothesis-generating and requires prospective validation before practice change.
Observational (n=818)
No
Does the presence of MAFLD increase the risk of AF recurrence after ablation in Japanese patients?
Effect estimate: HR 2.62 (95% CI 1.44-4.80)
p-value: p=0.002
MAFLD is an independent risk factor for AF recurrence after ablation in Japanese patients, particularly in those with insulin resistance, regardless of obesity.
Takami et al. (2025) conducted an observational in Atrial fibrillation (n=818). Metabolic dysfunction-associated fatty liver disease (MAFLD) vs. No MAFLD was evaluated on Atrial fibrillation recurrence (HR 2.62, 95% CI 1.44-4.80, p=0.002). Metabolic dysfunction-associated fatty liver disease independently increased the risk of atrial fibrillation recurrence after ablation in Japanese patients (adjusted HR 2.62).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: